Agenus (AGEN) Q4 2024 earnings summary

Executive summary

• Achieved significant reduction in annualized operational burn, targeting $50 million by mid-2025 through asset monetization and expense cuts to focus resources on lead programs.

• BOT/BAL program demonstrated transformative clinical outcomes in colorectal and other resistant cancers, with durable responses and prolonged survival in MSS CRC.

• External validation from leading oncology centers and investigator-sponsored trials supports BOT/BAL's potential.

• Ongoing discussions for partnerships and external funding to accelerate BOT/BAL clinical registration, especially in colorectal cancer.

Financial highlights

• Ended 2024 with $40.4 million in cash, down from $76.1 million at end of 2023.

• Cash used in operations for 2024 was $158.3 million, reduced from $224.2 million in 2023.

• 2024 revenue was $103.5 million, primarily from non-cash royalty revenue; net loss was $232.3 million ($10.59 per share).

• Q4 2024 revenue was $26.8 million, with a net loss of $46.8 million ($2.04 per share).

Outlook and guidance

• Strategic cost reductions continue, with further headcount and external advisor cuts to prioritize BOT/BAL development.

• Anticipates further reducing annual burn rate to $50 million by mid-2025 via externalization of development costs and asset monetization.

• Pipeline products have been shelved but can be quickly reignited as market conditions change.

• Key 2025 catalysts include regulatory updates and maturing clinical data for BOT/BAL.